Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ: BLUE )

3.700 -0.160 (-4.15%)
Streaming Delayed Price Updated: 12:59 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, investor! With our return from the weekend comes a dive into the biggest pre-market stock movers for Monday! 
Via InvestorPlace
New Data At ASH21 Show Bluebird's Thalassemia Gene Therapy Potentially Curative One-Time Treatment
Bluebird Bio Inc (NASDAQ: BLUE) presented new results for betibeglogene autotemcel (beti-cel), investigational gene therapy for β-thalassemia (beta-thal) who... 
Via Benzinga
Bluebird Bio Posts Updated Data From Sickle Cell Gene Therapy Program
Bluebird bio Inc (NASDAQ: BLUE) announced updated results from its Phase 1/2 HGB-206 study of lovotibeglogene autotemcel (lovo-cel; formerly LentiGlobin for SCD,... 
Via Benzinga
22 Stocks Moving in Monday's Pre-Market Session
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 32.6% to $3.58 in pre-market trading after gaining more than 14% on Friday. Foghorn Therapeutics Inc. (NASDAQ: FHTX) rose... 
Via Benzinga
New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJM
From bluebird bio, Inc.
Via Business Wire
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... 
Via Benzinga
Exposures Product Safety
New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels
From bluebird bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers iSpecimen (NASDAQ:ISPC) stock rose 31.09% to $6.45 during Monday's pre-market session. The company's market cap stands at $44.9 million. Provention Bio (... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, traders! We're getting right into the week with a breakdown of the biggest pre-market stock movers for Monday! 
Via InvestorPlace
Exposures Product Safety
Bluebird Bio's Thalassemia Gene Therapy Under Priority Review With FDA
The FDA has accepted Bluebird bio Inc's (NASDAQ: BLUE) marketing application for betibeglogene autotemcel (beti-cel) for β-thalassemia. The agency has... 
Via Benzinga
Exposures Product Safety
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
64 Biggest Movers From Yesterday
Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced the launch of its E-Boost portfolio of mobile... 
Via Benzinga
Why Bluebird Bio Stock Plunged Today
Two analysts downgraded the biotech stock. 
Via The Motley Fool
Market Rally Continues as Dow Nabs Intraday Highs
S&P 500 Index and Nasdaq Composite are sporting modest gains, with the Dow locking in another fresh intraday high. 
Via Talk Markets
Topics Stocks
Exposures US Equities
38 Stocks Moving In Monday's Mid-Day Session
Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares climbed 129.8% to $7.49 after the company announced the launch of its E-Boost portfolio of mobile Electric Vehicle... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers PetVivo Holdings (NASDAQ:PETV) s... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021
Upgrades For Nektar Therapeutics (NASDAQ: 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Chinook Therapeutics (NASDAQ:KDNY) shares increased by 28.75% to $15.76 during Friday's regular session. Trading volume for this security as of 12:30 EST is 1.... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Ontrak (NASDAQ:OTRK) shares rose 21.82% to $11.78 during Friday's pre-market session. The market value of their outstanding shares is at $225.5 million. As per... 
Via Benzinga
92 Biggest Movers From Friday
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the... 
Via Benzinga
64 Stocks Moving In Friday's Mid-Day Session
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the... 
Via Benzinga
bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress
From bluebird bio, Inc.
Via Business Wire
bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row
From bluebird bio, Inc.
Via Business Wire
28 Stocks Moving in Friday's Pre-Market Session
Gainers ReWalk Robotics Ltd. (NASDAQ: RWLK) rose 65.8% to $2.14 in pre-market trading after the company announced its ReBoot device has been granted designation as a Breakthrough... 
Via Benzinga
bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc
Via Business Wire
bluebird bio Completes Planned Business Separation
From bluebird bio, Inc.
Via Business Wire
Bluebird Bio To Withdraw Marketing Of Skysona Gene Therapy In Europe
Bluebird Bio Inc (NASDAQ: BLUE) will withdraw the regulatory marketing authorization for Skysona (elivaldogene autotemcel) in the European Union. The update comes... 
Via Benzinga
Could This Beaten-Down Biotech Stock Be the Next Buyout Target?
This gene-therapy specialist may need some help turning things around. 
Via The Motley Fool
bluebird bio Sets Record Date and Distribution Date for Planned Business Separation
From bluebird bio, Inc.
Via Business Wire
Bluebird Bio or Heron Therapeutics: Which Stock Is the Better Comeback Play?
These once-promising biotech stocks are trading at a fraction of their all-time highs right now. 
Via The Motley Fool
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.